Finance

Lists
MAZE:NASDAQ
Maze Therapeutics Inc
$25.87
0.00%
(0.00) 1D
$26.25
+1.47% (+0.38)
Pre-market
Closed: Sep 3, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MAZE...
Mkt. cap
1.44B
Avg. vol.
363.74K
Volume
681.00
52-wk high
$53.65
52-wk low
$14.27
EPS
-$2.51
Shares outstanding
55.55M
No. of employees
141
Mkt. cap
1.44B
Avg. vol.
363.74K
Volume
681.00
52-wk high
$53.65
52-wk low
$14.27
EPS
-$2.51
Shares outstanding
55.55M
No. of employees
141
News stories
From web sources and news partners
About Maze Therapeutics Inc
CEO-
Employees141
Founded2017
HeadquartersSouth San Francisco, California, United States
SectorPharmaceutical industry
Websitemazetx.com
Analyst ratings
Based on 7 analysts giving stock ratings to MAZE in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for MAZE in the last 3 months.
Highest
Current $25.87
$110.00 (+325.20%)
Average
$68.14 (+163.39%)
Lowest
$46.00 (+77.81%)
Analyst
Recommendation
Action
Price target
Projected
Date
Danielle Brill
Truist Financial
Buy
Maintained
$64.00
+147.4%
08/13/2026
Laura Chico
Wedbush
Buy
Maintained
$48.00
+85.5%
08/12/2026
Julian Harrison
BTIG
Buy
Maintained
$46.00
+77.8%
08/11/2026
Sadia Rahman
Wells Fargo
Buy
Reiterated
$55.00
+112.6%
08/12/2026
Ananda Ghosh
H.C. Wainwright
Buy
Maintained
$110.00
+325.2%
08/12/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
$57.00
+120.3%
08/12/2026
Salim Syed
Mizuho Securities
Buy
Maintained
$97.00
+275%
06/23/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
$53.00
+104.9%
05/22/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/12/2026
Martin Auster
Raymond James
Buy
Reiterated
$56.00
+116.5%
03/25/2026
Joseph Schwartz
Leerink Partners
Buy
Reiterated
$50.00
+93.3%
03/25/2026
Debjit Chattopadhyay
Guggenheim
Buy
Reiterated
$58.00
+124.2%
03/04/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
20.00M
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
25.19M
27.57M
34.15M
34.94M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.78M
10.49M
12.40M
13.10M
Operating expense
32.96M
38.06M
46.55M
48.04M
Total operating expenses
32.96M
38.06M
46.55M
48.04M
Operating income
-32.96M
-38.06M
-26.55M
-48.04M
Other non operating income
-
-
-
-
EBT including unusual items
-30.09M
-34.57M
-24.21M
-44.73M
EBT excluding unusual items
-30.09M
-34.57M
-24.21M
-44.73M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-30.09M
-34.57M
-24.21M
-44.73M
Net profit margin
-
-
-121.04%
-
Earnings per share
-0.66
-0.65
-0.45
-0.76
Interest and investment income
2.88M
3.49M
3.21M
4.24M
Interest expense
-
-
-866.00K
-931.00K
Net interest expenses
2.88M
3.49M
2.34M
3.31M
Depreciation and amortization charges
-
-
-
-
EBITDA
-32.39M
-37.56M
-26.11M
-47.64M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps